Roche agreed to acquire PathAI in a transaction valued at up to $1.05 billion to strengthen its digital pathology capabilities and expand AI-enabled diagnostic workflows. Roche will pay $750 million upfront, with up to $300 million more tied to milestones, and expects to close in the second half of 2026 subject to approvals. The acquisition builds on a long-running Roche–PathAI partnership that began in 2021 and expanded in 2024 to include AI-enabled companion diagnostic algorithms. Roche said it plans to merge PathAI into its Diagnostics division and scale PathAI’s Image Management System (IMS) globally, combining workflow analysis tools with Roche’s oncology diagnosis infrastructure. Roche also pointed to PathAI’s regulatory progress, including an FDA qualification for AIM-NASH (Histologic Measurement of NASH) to support scoring disease activity in metabolic dysfunction-associated steatohepatitis clinical trials. The deal highlights how pharma is using platform acquisitions to accelerate adoption of AI in trial and companion diagnostics development.